Source Monitoring Déficit in Neuropsychiatric Population

NCT ID: NCT03886584

Last Updated: 2025-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-08

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the investigators will measure source-monitoring ability in patients with several neuropsychiatric condition and in healthy controls appaired in age, sex and educational level. Source-monitoring will be measured thanks to internal- and reality-monitoring informatic tasks.The investigators hypothesized patients with fronto-temporal abnormalities would show more marked deficits than patients with only frontal abnormalities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Source-monitoring abilities will be measured thanks to reality-monitoring testing (i.e. the ability to distinguish internal-generated events from external ones) and internal-monitoring testing (i.e. the ability to distinguish an imagined source from a performed one). A source-monitoring deficit have been demonstrated in patients with psychiatric conditions such as schizophrenia and seems linked to frontotemporal abnormalities (frontotemporal dysconnectivity and temporal hypoactivity). With a total of 150 patients, the investigators will include 30 patients per group: patients with pre-dementia stage Alzheimer, Alzheimer, Fronto-Temporal dementia, Lewy Body dementia or Parkinson and Bipolar Disorder, with the hypothesis that Bipolar Disorder patients will present less marked deficit. The investigators will recruit 150 healthy controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychiatric Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

2 arms
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with with neuropsychiatric conditions

In this arm, five groups :

* Patients with DFT, diagnosed according Racovsky criteria
* Patients with Lewi Body dementia, diagnosed according McKeith criteria
* Patients with pre-demential Alzheimer, diagnosed according Dubois criteria
* Patients with Alzheimer, diagnosed according MMSE
* Patients with bipolar disorder, diagnosed according DSM 5

Group Type EXPERIMENTAL

Monitoring source test

Intervention Type OTHER

Internal- and external-monitoring correct responses and inversions

Healthy subjects

Healthy controls appaired in age, sex and educational level

Group Type ACTIVE_COMPARATOR

Monitoring source test

Intervention Type OTHER

Internal- and external-monitoring correct responses and inversions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monitoring source test

Internal- and external-monitoring correct responses and inversions

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who gave their free and informed consent;
* Men and women;
* Aged 18 to 80;
* Having normal or corrected vision;
* Mastering the French language (read and spoken);
* All subjects will not have a working memory deficit preventing the test from being passed (MMSE short version):AM patients should have a score of \<MMSE \<26; Patients with pre-dementia AD will be diagnosed according to Dubois criteria (Dubois et al., 2016); patients with early FTD will be diagnosed according to Rascovsky's criteria (Rascovsky et al., 2011); Patients with DCL will be diagnosed according to McKeith's criteria (McKeith et al., 2005), TBP patients will be diagnosed using DSM 5 criteria (Arlington VA, 2013).

Exclusion Criteria

* Inadmissibility of the consent or refusal of the subject.
* Patients under guardianship
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hôpital le Vinatier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

JEROME BRUNELIN, PHD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Le Vinatier - CRNL - INSERM

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Le Vinatier

Bron, Auvergne-Rhône-Alpes, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

JEROME BRUNELIN, PHD

Role: CONTACT

00334 37 91 55 65

Jean-Michel DOREY, PHD

Role: CONTACT

00334 37 91 52 49

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

VIAL VERONIQUE

Role: primary

0033437915531

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A00584-51

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.